How do you know the trial failed for under 45’s? It may appear simple but as a reminder for the rest of us,
• ViralezeTM achieved a statistically significant reduction in SARS-CoV-2 viral load, the primary endpoint of the study, in the cohort of participants aged 45 and over (N=118, p=0.017).
• ViralezeTM reduced viral load in the full study population including all patient age groups (N=197), although the difference vs placebo was not statistically significant.
The p value for 45 years and over was 0.017.
Statistical significance is generally recognised as 0.05 or lower.
So, did the p value shoot up to 0.051 for the age group 44 and above? I don’t think so.
How about 43 and above? Or 42? 41?
We don’t know, so perhaps viraleze is good for 40+. Or perhaps 35+. Perhaps even 30+!
We do know it is not approved for under 18’s
At some point the p value reached 0.051 but it could have been when N =196. Again we don’t know. (Well, I don’t know!)
For whatever reason, the company has identified 45+ and that still needs to be explained and charted.
- Forums
- ASX - By Stock
- Ann: Viraleze shows antiviral efficacy in COVID-19 patients
How do you know the trial failed for under 45’s? It may appear...
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.4¢ |
Change
0.001(1.08%) |
Mkt cap ! $38.76M |
Open | High | Low | Value | Volume |
9.4¢ | 9.4¢ | 9.4¢ | $155 | 1.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8988 | 9.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.6¢ | 55000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8988 | 0.094 |
1 | 249999 | 0.093 |
1 | 60000 | 0.092 |
1 | 10900 | 0.090 |
2 | 147200 | 0.087 |
Price($) | Vol. | No. |
---|---|---|
0.096 | 55000 | 2 |
0.097 | 60000 | 1 |
0.098 | 65000 | 1 |
0.099 | 48700 | 1 |
0.100 | 111205 | 3 |
Last trade - 10.43am 08/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |